Summary & Overview
HCPCS J0462: Atropine Sulfate Injection, 0.01 mg
HCPCS Level II code J0462 designates a specific injectable formulation of atropine sulfate (0.01 mg) that is not therapeutically equivalent to J0461. As a drug administration code, it matters nationally for billing, inventory, and clinical documentation where exact drug formulation or manufacturer distinctions affect payer adjudication and clinical use. Precise coding ensures correct product identification for pharmacovigilance and reimbursement.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise review of the clinical context for atropine injection, typical sites of service (outpatient clinics, emergency departments, and inpatient settings), and the implications of using a non-equivalent drug code. The publication summarizes available benchmarks and policy-relevant considerations for payers, highlights areas where coding specificity can affect claims processing, and outlines what documentation is generally needed to support use of a distinct drug code.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes is noted where relevant. The piece is written for a national audience seeking clear guidance on the coding and administrative context of J0462.
Billing Code Overview
HCPCS Level II code J0462 represents an injection of atropine sulfate, specified as not therapeutically equivalent to J0461, in a dose of 0.01 mg. This code denotes a medication administration service involving a specific formulation or manufacturer of atropine sulfate that is distinct from the product identified by J0461.
Service Type: Drug administration / injectable medication
Typical Site of Service: Outpatient clinic, emergency department, or inpatient bedside administration, depending on clinical need and facility practice. If more specific site-of-service guidance is required, Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an emergency department or perioperative setting where a clinician administers J0462 (injection, atropine sulfate, not therapeutically equivalent to J0461, 0.01 mg) for acute symptomatic bradycardia, organophosphate or nerve agent exposure with cholinergic crisis, or as pre-anesthetic anticholinergic therapy in select cases. A 68-year-old patient arrives with symptomatic sinus bradycardia (dizziness, hypotension, syncope). The emergency physician orders intravenous J0462 titrated to effect while continuous cardiac monitoring and IV access are established. Documentation captures indication, dose administered, route (IV), time, response, and any concurrent resuscitation measures. Typical workflow includes patient assessment, indication confirmation, consent as appropriate (emergent consent implied when indicated), medication preparation by nursing or pharmacy, administration with specified dose units billed per 0.01 mg increment, monitoring for anticholinergic adverse effects, and post-administration vital signs and disposition planning (admit, observe, or transfer). Typical sites of service are Emergency Department, Inpatient Hospital, Intensive Care Unit, and Preoperative Holding Area. Billing uses appropriate medical necessity documentation and applicable modifiers for circumstances such as outpatient observation, inpatient services, or wasted medication when portions remain unused.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|